Fintel reports that on May 26, 2023, HC Wainwright & Co. reiterated coverage of PDS Biotechnology (NASDAQ:PDSB) with a Buy recommendation.
Analyst Price Forecast Suggests 188.39% Upside
As of May 11, 2023, the average one-year price target for PDS Biotechnology is 19.38. The forecasts range from a low of 12.12 to a high of $26.25. The average price target represents an increase of 188.39% from its latest reported closing price of 6.72.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for PDS Biotechnology is 0MM. The projected annual non-GAAP EPS is -1.20.
What is the Fund Sentiment?
There are 104 funds or institutions reporting positions in PDS Biotechnology. This is an increase of 9 owner(s) or 9.47% in the last quarter. Average portfolio weight of all funds dedicated to PDSB is 0.03%, a decrease of 42.21%. Total shares owned by institutions increased in the last three months by 12.38% to 7,710K shares. The put/call ratio of PDSB is 0.11, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 755K shares representing 2.46% ownership of the company. No change in the last quarter.
Millennium Management holds 596K shares representing 1.94% ownership of the company. In it’s prior filing, the firm reported owning 451K shares, representing an increase of 24.31%. The firm decreased its portfolio allocation in PDSB by 36.21% over the last quarter.
Two Sigma Investments holds 589K shares representing 1.92% ownership of the company. In it’s prior filing, the firm reported owning 496K shares, representing an increase of 15.72%. The firm decreased its portfolio allocation in PDSB by 49.68% over the last quarter.
Two Sigma Advisers holds 584K shares representing 1.90% ownership of the company. In it’s prior filing, the firm reported owning 559K shares, representing an increase of 4.31%. The firm decreased its portfolio allocation in PDSB by 55.03% over the last quarter.
Renaissance Technologies holds 366K shares representing 1.19% ownership of the company. In it’s prior filing, the firm reported owning 247K shares, representing an increase of 32.37%. The firm decreased its portfolio allocation in PDSB by 33.19% over the last quarter.
PDS Biotechnology Background Information
(This description is provided by the company.)
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
